Note, Wegovy and Zepbound are the only two drugs approved to treat obesity in the US. Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro are approved in the US and UK for treating type 2 diabetes.
Tirzepatide, the main ingredient in both Zepbound and Mounjaro, was found in trials to achieve an average weight loss of 26% in one year. In Eli Lilly’s SURMOUNT-4 trial of 783 adults who were overweight or obese but without diabetes, random participants who took the drug for 36 weeks were switched to a placebo and at 88 weeks maintained a 9.5% weight loss from their baseline.
Ozempic, Wegovy, Mounjaro: Which is best for weight loss? (qz.com)
These drugs are causing loss of muscle, impaired digestion, loss of bile flow and pancreatitis. What's a good recovery protocol?
Leave a reply